Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE)

P680 Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn’s disease: results from IM-UNITI long-term extension through 2 years

(2019) S Ghosh et al.   Journal of Crohns & Colitis

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

(2018) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience

(2018) P. Wils et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease

(2018) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease

(2018) Paul Rutgeerts et al.   GASTROENTEROLOGY

Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohnʼs Disease

(2017) Christopher Ma et al.   INFLAMMATORY BOWEL DISEASES

Crohn's disease

(2017) Joana Torres et al.   LANCET

Ustekinumab use in Crohn’s disease: a Canadian tertiary care centre experience

(2017) Astrid-Jane Greenup et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents

(2016) Pauline Wils et al.   Clinical Gastroenterology and Hepatology

Patients with Refractory Crohnʼs Disease Successfully Treated with Ustekinumab

(2016) Kimberly A. Harris et al.   INFLAMMATORY BOWEL DISEASES

Ustekinumab for the Treatment of Refractory Crohnʼs Disease

(2016) Sam Khorrami et al.   INFLAMMATORY BOWEL DISEASES

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective

(2016) Jordan E Axelrad et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management

(2015) N. S. Ding et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience

(2014) U. Kopylov et al.   Journal of Crohns & Colitis

Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease

(2014) Taina Sipponen et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease

(2012) Clas-Göran af Björkesten et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity

(2010) Severine Vermeire et al.   Clinical Gastroenterology and Hepatology